Category: Latest News

The launch of Glatopa™ (glatiramer acetate injection) in the United States was announced yesterday by Sandoz, a Novartis company. Glatopa is manufactured by Sandoz and is the 13th medication to be approved by the FDA as a long-term, disease-modifying therapy for multiple sclerosis (MS). This generic version of Copaxone® (glatiramer acetate injection) was approved on April 16, 2015, for the treatment of individuals with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

My MS Manager™, the first-of-its kind mobile phone app created by the Multiple Sclerosis Association of America (MSAA) to help individuals with multiple sclerosis (MS) better manage their disease, now offers new features including a way to connect and share information with one’s physician.

The American Academy of Neurology’s (AAN’s) 67th Annual Meeting took place in Washington, DC April 18th-25th. The AAN is an association of more than 27,000 neurologists and neuroscience professionals dedicated to advancing the care of individuals with neurologic disease. Every year, these professionals gather to hear the latest findings in research and treatments for neurological conditions, including multiple sclerosis (MS). To follow are some important highlights.

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that James M. Anderson, Esquire, has been elected as the Chairman of their Board of Directors. Mr. Anderson is an attorney in Mississippi and the Managing Member of Anderson Crawley & Burke, pllc, a law firm headquartered in the Jackson, Mississippi area. He also maintains a second residence in Austin, Texas.

For the more than 400,000 Americans living with multiple sclerosis (MS), the support and resources available from organizations such as the Multiple Sclerosis Association of America (MSAA) are crucial to improving quality of life. Swim for MS – an ongoing national fundraiser – helps MSAA provide much-needed vital services and support for the MS community.

The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication at mymsaa.org. This vital resource provides new information on the research findings of the FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions for future research are also presented.

In August 2014, MSAA posted a news item announcing that the Multiple Sclerosis Coalition (MSC) had published a paper detailing the current evidence that supports the FDA-approved disease-modifying therapies (DMTs) for the long-term treatment of multiple sclerosis (MS). This paper was written expressly for healthcare providers and the health-insurance industry.

On April 16, 2015, the United States Food and Drug Administration (FDA) approved Glatopa™ (glatiramer acetate injection) for the treatment of individuals with relapsing forms of multiple sclerosis (MS), including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

Individuals living with multiple sclerosis (MS) often find that heat and humidity aggravate common MS symptoms. In addition to advice such as using air conditioning and sipping cool beverages throughout the day, individuals living with MS may also benefit from the use of special cooling equipment to help maintain an ideal body temperature.

For the more than 400,000 Americans living with multiple sclerosis (MS), the support of loved ones, care partners and organizations such as the Multiple Sclerosis Association of America (MSAA) is crucial to improving quality of life. To help increase awareness of this disease, MSAA is taking part in observing March as MS Awareness Month.